Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 40 of 102, showing 5 Applications out of 508 total, starting on record 196, ending on 200

# Protocol No Study Title Investigator(s) & Site(s)

196.

ECCT/21/09/08   GBT133_Inclacumab Open-Label
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated inread more
Principal Investigator(s)
1. Fredrick Sirwa Chite
2. Bernhards Ragama Ogutu
3. Videlis N Nduba
4. Prof Jessie N Githanga
Site(s) in Kenyaread more
View

197.

ECCT/21/09/02   PrEDIRA - 2
    Piloting HIV Pre-exposure Prophylaxis (PrEP) Integration into Services for Early Pregnancy Loss   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. KEMRI-CCR PHRD THIKA - Thika, Nairobi, Murang\'a, and their environs (Kiambu county)
2.read more
View

198.

ECCT/21/07/04   Healthy Route
    A Non-Interventional Pilot Study to Evaluate A Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rateread more
Principal Investigator(s)
1. Mansoor Noorali Saleh
2. Videlis Nduba
Site(s) in Kenya
1. Aga Khan University Hospital Clinical Research Unit (Nairobi Cityread more
View

199.

ECCT/21/07/05   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine fromread more
Principal Investigator(s)
1. Dr Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. KEMRI Walter Reed Project (read more
View

200.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cellread more
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-read more
View